An observational study in Motor Delay, Neurodevelopmental Disorders and Developmental Disability, sponsored by Shirley Ryan AbilityLab. Active, not recruiting at 2 sites in United States. Open to participants aged 0 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Shirley Ryan AbilityLab · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Psychomotor Disorders with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Psychomotor Disorders · United States.
Among the 15 studies in Psychomotor Disorders with a site in United States, this one is one of 2 that started in 2019, is one of 5 observational ones, and was the 6th registered.
51 studies on the registry are indexed under Psychomotor Disorders; 8 are open to participants now.
Browse Psychomotor Disorders studies →5 of the 15 studies in Psychomotor Disorders with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 1–6
Ohio State University · Sites in United States
Ages up to 10 days
University of Missouri-Columbia · Sites in United States
Ages 0–99
Emory University · Sites in United States
Ages 18–65
Shirley Ryan AbilityLab · Sites in United States
Ages 0 days–52 wk
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Psychomotor Disorders studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 0 Months to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 69 across 13 observational studies indexed under Psychomotor Disorders.
Median enrollment 60 across the 9 interventional studies, 50 across the 5 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
Shirley Ryan AbilityLab is the lead sponsor of 181 studies on the registry; 44 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
Shirley Ryan AbilityLab has 3 studies filed under Psychomotor Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Psychomotor Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03770832Shirley Ryan AbilityLabWearable Sensors and Video Recordings to Monitor Motor Development | 2026-12 |
| NCT05568264Shirley Ryan AbilityLabEffects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit | 2026-12-31 |
| NCT06399952University of Missouri-ColumbiaBaker Gordon Syndrome Natural History Study | 2027-05-05 |
| NCT05849038Emory UniversityInflammation and Depression in People With HIV | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Psychomotor Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to develop an automated, precise, quantitative assay for detecting atypical motor behavior and development in infants using data from wearable sensors and video recordings.
Individuals at high risk of developing motor delays \<24 months of age along with infants at low risk of developing motor delays.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Three month clinical score estimation
Error between true clinical test scores and scores estimated from sensor and video data, assessed at the 3 month time-point.
Time frame: 3 months
Six month clinical score estimation
Error between true clinical test scores and scores estimated from sensor and video data, assessed at 6 month time-point.
Time frame: 6 months
Prediction of neuromotor outcome using sensor and video data from 3 month time-point
Sensitivity and specificity of algorithm (trained on sensor and video data from the 3 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])
Time frame: 3 months
Prediction of neuromotor outcome using sensor and video data from 6 month time-point
Sensitivity and specificity of algorithm (trained on sensor and video data from the 6 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])
Time frame: 6 months
Prediction of neuromotor outcome using General Movements Assessment (GMA) scores
Sensitivity and specificity of GMA scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]). The GMA is an observational exam where an infant's spontaneous movements are scored as atypical or normal for their age.
Time frame: 1-2 weeks, 1 month, 3 months
Prediction of neuromotor outcome using Alberta Infant Motor Scale (AIMS) scores
Sensitivity and specificity of AIMS scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]). The AIMS is a norm-referenced observational assessment with a minimum score of 0 and a maximum score of 58. Higher scores indicate better motor performance on the assessment.
Time frame: 6 months, 9 months, 1 year
Prediction of neuromotor outcome using Hammersmith Infant Neurological Examination (HINE) scores
Sensitivity and specificity of HINE scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]). The HINE is a neurological exam with a minimum score of 0 and a maximum score of 78. Higher scores indicate better performance on the assessment.
Time frame: 6 months, 9 months, 1 year
Prediction of neuromotor outcome using Test of Infant Motor Performance (TIMP) scores
Sensitivity and specificity of TIMP scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\]).
Time frame: 1-2 weeks, 1 month, 3 months
Clinical score estimation
Error between true clinical test scores and scores estimated from sensor and video data, assessed at each remaining time-point.
Time frame: 1-2 weeks, 1 month, 9 months, 1 year, 2 years
Prediction of neuromotor outcome at 2 years using sensor and video data from the remaining time-points
Sensitivity and specificity of algorithm (trained on sensor and video data from the remaining time-points) to predict neuromotor outcome at 2 years (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])
Time frame: 1-2 weeks, 1 month, 9 months, 1 year, 2 years
Prediction of neuromotor outcome using NICU Network Neurobehavioral Scale (NNNS) scores
Sensitivity and specificity of NNNS scores (taken at 1 month) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition \[PDMS-2\])
Time frame: 1 month
Started Mar 2019 (actual). Primary completion is estimated for Dec 2026, 93 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.